Mycobacterium tuberculosis infection in liver transplantation

Liver Transplantation

Volumn 16, Issue 10, 2010, Pages 1129-1135

  Yehia, Baligh R ^a   Blumberg, Emily A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; BCG VACCINE; CALCINEURIN INHIBITOR; CYCLOSPORIN; ETHAMBUTOL; IMMUNOSUPPRESSIVE AGENT; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MOXIFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; TACROLIMUS; TUBERCULOSTATIC AGENT;

ARTHRALGIA; BCG VACCINATION; CLINICAL FEATURE; DRUG RESISTANT TUBERCULOSIS; GRAFT RECIPIENT; HUMAN; INFECTION RISK; INTERFERON GAMMA RELEASE ASSAY; INTERMETHOD COMPARISON; LATENT TUBERCULOSIS; LIVER FUNCTION TEST; LIVER TOXICITY; LIVER TRANSPLANTATION; MYCOBACTERIUM TUBERCULOSIS; NEPHROTOXICITY; OTOTOXICITY; PRIORITY JOURNAL; REVIEW; THORAX RADIOGRAPHY; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT RESPONSE; TUBERCULIN TEST; TUBERCULOSIS; DRUG EFFECT; DRUG INTERACTION; GRAFT REJECTION; GRAFT SURVIVAL; MICROBIOLOGY; MORTALITY; PATHOGENICITY; PREDICTIVE VALUE; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME;

ANTITUBERCULAR AGENTS; DRUG INTERACTIONS; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LATENT TUBERCULOSIS; LIVER TRANSPLANTATION; MYCOBACTERIUM TUBERCULOSIS; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUBERCULIN TEST; TUBERCULOSIS;

EID: 79951781723     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22133     Document Type: Review

References (27)

1. WHO Report 2009: Global Tuberculosis Control: Epidemiology, Strategy, Financing. Geneva, Switzerland: World Health Organization; 2009.
2. Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis 1998;27: 1266-1277.
3. Munoz P, Rodriguez C, Bouza E. Mycobacterium tuberculosis infection in recipients of solid organ transplants. Clin Infect Dis 2005;40:581-587.
4. Torre-Cisneros J, Doblas A, Aguado JM, San Juan R, Blanes M, Montejo M, et al. Tuberculosis after solidorgan transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort. Clin Infect Dis 2009;48:1657-1665.
5. Aguado JM, Torre-Cisneros J, Fortun J, Benito N, Meije Y, Doblas A, Munoz P. Tuberculosis in solid-organ transplant recipients: consensus statement of the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology. Clin Infect Dis 2009;48: 1276-1284.
6. Subramanian A, Dorman S. Mycobacterium tuberculosis in solid organ transplant recipients. Am J Transplant 2009;9(SUPPL. 4):S57-S62.
7. Holty JE, Gould MK, Meinke L, Keeffe EB, Ruoss SJ. Tuberculosis in liver transplant recipients: a systematic review and meta-analysis of individual patient data. Liver Transpl 2009;15:894-906.
8. Clemente WT, Faria LC, Lima SS, Vilela EG, Lima AS, Velloso LF, et al. Tuberculosis in liver transplant recipients: a single Brazilian center experience. Transplantation 2009;87:397-401.
9. Wang B, Lu Y, Yu L, Liu C,Wu Z, Pan C. Diagnosis and treatment for tuberculosis infection in liver transplant recipients: case reports. Transplant Proc 2007;39:3509-3511.
10. Zhang XF, Lv Y, Xue WJ, Wang B, Liu C, Tian PX, et al. Mycobacterium tuberculosis infection in solid organ transplant recipients: experience from a single center in China. Transplant Proc 2008;40:1382-1385.
11. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007;146:340-354.
12. Manuel O, Humar A, Preiksaitis J, Doucette K, Shokoples S, Peleg AY, et al. Comparison of QuantiFERON-TB gold with tuberculin skin test for detecting latent tuberculosis infection prior to liver transplantation. Am J Transplant 2007;7:2797-2801.
13. Richeldi L, Losi M, D'Amico R, Luppi M, Ferrari A, Mussini C, et al. Performance of tests for latent tuberculosis in different groups of immunocompromised patients. Chest 2009;136:198-204.
14. Marquez M, Fernandez-Gutierrez C, Montes-de-Oca M, Blanco MJ, Brun F, Rodriguez-Ramos C, et al. Chronic antigenic stimuli as a possible explanation for the immunodepression caused by liver cirrhosis. Clin Exp Immunol 2009;158:219-229.
15. Antoniades CG, Berry PA, Wendon JA, Vergani D. The importance of immune dysfunction in determining outcome in acute liver failure. J Hepatol 2008;49:845-861.
16. Wasmuth HE, Kunz D, Yagmur E, Timmer-Stranghoner A, Vidacek D, Siewert E, et al. Patients with acute on chronic liver failure display sepsis-like immune paralysis. J Hepatol 2005;42:195-201.
17. Hsu MS, Wang JL, Ko WJ, Lee PH, Chou NK, Wang SS, et al. Clinical features and outcome of tuberculosis in solid organ transplant recipients. Am J Med Sci 2007; 334:106-110.
18. Society AT. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep 2000; 49:1-51.
19. Kiuchi T, Inomata Y, Uemoto S, Satomura K, Egawa H, Okajima H, et al. A hepatic graft tuberculosis transmitted from a living-related donor. Transplantation 1997; 63:905-907.
20. Chan AC, Lo CM, Ng KK, Chan SC, Fan ST. Implications for management of Mycobacterium tuberculosis infection in adult-to-adult live donor liver transplantation. Liver Int 2007;27:81-85.
21. Organ Procurement and Transplant Network. Data reports. http://optn.transplant.hrsa.gov/latestData/rptData. asp. Accessed July 2010.
22. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American Thoracic Society/ Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167: 603-662.
23. Singh N, Wagener MM, Gayowski T. Safety and efficacy of isoniazid chemoprophylaxis administered during liver transplant candidacy for the prevention of posttransplant tuberculosis. Transplantation 2002;74:892-895.
24. Jahng AW, Tran T, Bui L, Joyner JL. Safety of treatment of latent tuberculosis infection in compensated cirrhotic patients during transplant candidacy period. Transplantation 2007;83:1557-1562.
25. Aguado JM, Herrero JA, Gavalda J, Torre-Cisneros J, Blanes M, Rufi G, et al. Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Transplantation 1997;63: 1278-1286.
26. Munoz P, Palomo J, Munoz R, Rodriguez-Creixems M, Pelaez T, Bouza E. Tuberculosis in heart transplant recipients. Clin Infect Dis 1995;21:398-402.
27. Lee J, Yew WW, Wong CF, Wong PC, Chiu CS. Multidrugresistant tuberculosis in a lung transplant recipient. J Heart Lung Transplant 2003;22:1168-1173.